USPTO serial 97594393
AFFIMED
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 23, 2024
- Examiner
- GAYNOR, BARBARA ANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AFFIMED?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shauna M. Wertheim
Shauna M. Wertheim THE MARBURY LAW GROUP, PLLC11800 SUNRISE VALLEY DRIVE15TH FLOORRESTON, VA 20191Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological and biochemical preparations, in particular in form of antibodies, antibody derivatives, binding proteins and peptides for scientific laboratory and scientific experimentation purposes, in particular for conducting experimental assays, all of the foregoing other than for medical or veterinary purposes | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations, namely, pharmaceutical and veterinary preparations used for tumour treatment, cancer treatment, and immunotherapy purposes; biological and biochemical preparations in form of antibodies, antibody derivatives, binding proteins and peptides for medical or veterinary purposes, all used for tumour treatment, cancer treatment, and immunotherapy purposes; biological and biochemical preparations for medical or veterinary purposes and in the form of bifunctional or multifunctional proteins with binding affinity to immune cells, in particular with binding affinity to T cells and natural killer (NK) cells, in particular for the subsequent targeting of cancer cells; biological and biochemical preparations for medical or veterinary purposes and for diagnostic and therapeutic use, in particular in form of antibodies, antibody derivatives, binding proteins and peptides, all used for treatment of cancer, treatment of tumours, and immunotherapy purposes; biological and biochemical preparations in form of antibodies, antibody derivatives, binding proteins and peptides for use within the framework of experimental and medical or veterinary assays, all used for treatment of cancer, treatment of tumours, and immunotherapy purposes | ACTIVE | — |
| 042 | Scientific and technological services in the nature of scientific and technological research, research in the nature of medical and pharmaceutical research and design in the nature of new product design, all in the field of immunotherapy, in particular in the field of immuno-oncology; scientific and technological services in the nature of scientific and technological research, research in the nature of medical and pharmaceutical research and design in the nature of new product design, all in the field of virology; scientific and technological services in the nature of scientific and technological research, research in the nature of medical and pharmaceutical research and design in the nature of new product design and engineering design, all in the field of antiinfectives; scientific and technological services in the nature of scientific and technological research, research in the nature of medical and pharmaceutical research, and design in the nature of new product design, all in the field of neurodegenerative diseases; scientific and technological services in the nature of scientific and technological research, research in the nature of medical and pharmaceutical research and design in the nature of new product design, all in the field of autoimmune diseases; in particular all of the aforesaid services related to the use of antibodies, antibody derivatives, binding proteins and peptides; scientific and technological services in the nature of scientific and technological research, research in the nature of medical and pharmaceutical research and design in the nature of new product design, all in the field of immunotherapy by means of activating or modulating innate and adaptive immunity, in particular in the field of immune-oncology; industrial analysis and research services, namely, industrial research in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Affimed GmbH
- Other trademarks owned by Affimed GmbH
- Other trademarks owned by Affimed GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named AFFIMED
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 23, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 23, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 4, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 7, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 7, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 18, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 6, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 6, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 6, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 2, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 15, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 15, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 15, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 3, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 4, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 3, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 20, 2022 | NWAP | NEW APPLICATION ENTERED | — |